FDA & Government News
The Latest
Advances in Crohn’s disease therapies show similar safety
-
by Doug Brunk
Large claims analysis finds no significant differences in serious infections, VTE, or MACE across biologics and JAK inhibitors.
Expert spotlights advances in ulcerative colitis treatment
-
by Doug Brunk
“Appendicectomy is a viable and safe strategy for reducing the relapse rate in patients with UC compared to standard medical therapy alone,” Dr. Kara De Felice said.
New Crohn's data spotlight promising therapies
-
by Doug Brunk
Beyond drugs, interest is growing in diet-based treatments.
FDA issues early alert for AXIOS System
-
by Doug Brunk
The alert follows reports of deployment problems that may lead to serious injury, procedural complications, and even death.
Ranitidine’s return 'unlikely to provide greater clinical benefit'
-
by Doug Brunk
New formulation incorporates stronger manufacturing controls and stability measures to prevent a possible carcinogen from forming.
Letter from the editor: The aftermath of Kennedy vs Braidwood
-
by Megan A. Adams, MD, JD, MSc
The fight to protect science-based health policy is far from over.
An uncertain future for no-cost preventive care
-
by Megan A. Adams, MD, JD, MSc
Despite a new administration, the federal government continues to advocate for upholding the law, asserting that USPSTF members are “inferior officers."
